Who has invested in CymaBay Therapeutics?

Gilead Sciences are named among the investors backing CymaBay Therapeutics.

CymaBay Therapeutics Funding: $4.3B Raised, IPO (2024)

CymaBay Therapeutics funding overview

CymaBay Therapeutics is based in Newark. CymaBay Therapeutics has raised $4.3B in total disclosed funding. That places its disclosed total in over $1B. Its most recent disclosed round is an IPO announced in March 2024. The round record for CymaBay Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Gilead Sciences.

CymaBay Therapeutics at a glance

Total raised: $4.3B
Latest round: IPO
Latest round date: March 2024
Headquarters: Newark
Notable investors: Gilead Sciences

Frequently asked about CymaBay Therapeutics funding

How much has CymaBay Therapeutics raised?: CymaBay Therapeutics has raised $4.3B in total disclosed funding across the rounds on record.
Who has invested in CymaBay Therapeutics?: Gilead Sciences are named among the investors backing CymaBay Therapeutics.
What was the latest CymaBay Therapeutics funding round?: The most recent disclosed round is an IPO, announced in March 2024.
Where is CymaBay Therapeutics based?: CymaBay Therapeutics is based in Newark.
When did CymaBay Therapeutics last raise?: The last disclosed CymaBay Therapeutics round closed in March 2024 at IPO.

Round data for CymaBay Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Newark and backer lists below.

CymaBay Therapeutics Funding: $4.3B Raised, IPO (2024)

CymaBay Therapeutics funding overview

CymaBay Therapeutics at a glance

Frequently asked about CymaBay Therapeutics funding

Companies related to CymaBay Therapeutics (40)

Browse related funding lists (3)